Medication Therapy Management Program (MTMP)

[2018_NAME] has programs that help members manage their Part D and other medications in special situations. For example, some members have several complex medical conditions at one time. These members may need to take many drugs at the same time, or they could have high drug costs. A team of pharmacists and doctors developed a program for us to help these members with their care. This program is called the Medication Therapy Management Program, or MTMP.

The MTMP can help make sure that our members are using the drugs that work best to treat their medical conditions, help us to identify possible medication errors, and help improve medication adherence. The program is not considered a benefit and is voluntary and free to eligible members.

Members who are eligible for the MTMP have:

  • Three or more of the following chronic disease states:
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Hypertension
    • Dyslipidemia
    • Osteoporosis
    • End Stage Renal Disease (ESRD)
    • Mental Health-Depression
    • Diabetes
  • Eight or more chronic or maintenance Part D medications
  • Most likely have higher drug costs (more than $3,919 each year)

If you meet the criteria for the MTMP, we will automatically enroll you in the program. An MTM pharmacist reviews your medication history and sends you a welcome letter indicating you have qualified for MTMP. The letter describes any potential medication related problems found during their review and invites you to call for a medication review with an MTM pharmacist. If you decide not to participate, please notify us and we will withdraw your participation in the program.

The pharmacist or pharmacy intern under the direct supervision of a pharmacist will provide the following MTMP services with a final goal of helping the member reach the best therapeutic results to fit their needs:

On January 1, 2018, our plan name will change from Bridgeway Health Solutions Medicare Advantage to Allwell from Health Net. 


Last Updated: 09/30/2017
H5590_18_4161WEB_Approved_09282017